TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01051479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11-Choline
Description: 15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
Study: NCT00159315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Challenge with ATP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inhalation Challenge with ATP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Challenge with AMP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inhalation Challenge with AMP
Study: NCT02787577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Lengthening
Description: Behaviour change techniques targeting sleep hygiene
Study: NCT03505372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast enhanced mammography
Description: Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
Study: NCT03552991

Intervention type: DRUG
Group type: OTHER
Intervention: Agiocur Pregranules
Description: 6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
Study: NCT04819165

Intervention type: OTHER
Intervention: COVID-19
Description: Impact of covid-19 on infections associated with health care devices.
Study: NCT01967459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
Study: NCT01119521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
Study: NCT03798418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: elastic band strengthening exercise
Description: 2-3days per week(150min per week)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: elastic band strengthening exercise
Description: 2-3days per week(150min per week)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet counseling
Description: each patients in this group will receive4-5times diet counseling
Study: NCT02882126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Treprostinil
Description: Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
Study: NCT01119690

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cold-pressed turnip rapeseed oil (CTPRO)
Description: 1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk fat
Description: 1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.~2. In the 5-hour oral glucose and fat tolerance test: glucose and cream
Study: NCT01834339

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVPOME
Study: NCT01217827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Reminder
Study: NCT06041906

Intervention type: PROCEDURE
Intervention: Shunt Closure
Description: Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
Study: NCT01439035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OFDI Imaging
Description: Imaging of Duodenum with OFDI system
Study: NCT03345381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKY + ASTM + usual care
Description: Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment as usual
Study: NCT00387322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT02672943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-rehabilitation treatment
Description: The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
Study: NCT02698943

Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Phacoemulsification for cataract extraction with Envista MX-60 implantation
Study: NCT03691272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS - Real Air Film Coil
Description: 70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS - Sham Coil
Description: A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
Study: NCT01855971

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same capsules containing rice flour. No active treatment is given.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training
Description: Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
Study: NCT03568773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (\> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise moderate intensity
Description: The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, \<threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
Study: NCT01364792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valaciclovir
Description: 4 times 2 grams valaciclovir per day, administrated orally, for seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: 4 times 2 grams valaciclovir per day, administrated orally, for seven days.
Study: NCT00285662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo
Description: Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo
Description: Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo
Description: Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
Study: NCT00095056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glipizide
Description: One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glipizide
Description: One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glipizide
Description: One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
Study: NCT04961177

Intervention type: OTHER
Group type: OTHER
Intervention: EITC & ACEs Training
Description: We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.

Intervention type: OTHER
Group type: OTHER
Intervention: EITC Outreach & Screening
Description: Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each).

Intervention type: OTHER
Group type: OTHER
Intervention: Assistance with EITC
Description: We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey.
Study: NCT00159939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prone positioning
Description: prone positioning
Study: NCT00769652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy
Description: Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during \& after treatment.
Study: NCT03679715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participatory art-based activity
Description: The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops.
Study: NCT01784120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin/Genexol-PM
Study: NCT02731690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceneuramic Acid Extended-Release
Description: oral tablets
Study: NCT04519905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Description: Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Different radiotherapy dose in different groups.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Different radiotherapy dose in different groups.
Study: NCT01689935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 % Aminolevulinic Acid
Description: topical medication for ALA-PDT and i-PDT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 % Aminolevulinic Acid
Description: topical medication for ALA-PDT and i-PDT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red light only
Description: Red Light therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light only
Description: Blue light only

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light only
Description: Blue light only
Study: NCT01074918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium, Magnesium, Citrate
Description: Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: Potassium Chloride
Study: NCT05350280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric current
Description: Electric current will be applied in this group of patients using removable device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: No acceleration method will be performed in this group.
Study: NCT04546503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Regional analgesia
Description: Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~+ General anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: General anaesthesia without regional analgesia
Study: NCT00387322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study: NCT01836068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
Study: NCT04940975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupation-based sleep intervention program
Description: A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
Study: NCT03361241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Physiotherapeutic Intervention
Description: Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic Intervention
Description: Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
Study: NCT04996420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearsight non invasive hemodynamic monitoring
Description: Goal directed fluid therapy fuided by Clearsight monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: Clearsight non invasive hemodynamic monitoring
Description: Goal directed fluid therapy fuided by Clearsight monitoring
Study: NCT02923700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich PRP intra-articular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor PRP intra-articular injections
Study: NCT00314158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Description: One drop twice daily in each study eye for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension
Description: One drop twice daily in each study eye for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 5 mg/ml eye drops, solution
Description: One drop twice daily in each study eye for six months
Study: NCT03686072

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract surgery with endoscopic goniosynechialysis
Description: Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
Study: NCT03160716

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Lyft with Lidocaine
Description: a sterile gel of hyaluronic acid (HA)